Drug Trial Radar · NCT06649292
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
524
Planned (sponsor's estimate)
Start
Nov 22, 2024
Primary completion
Sep 20, 2027
Study completion Mar 20, 2028
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
Conditions
- Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
SHR-A1904Drug
SHR-A1904
Paclitaxel, Docetaxel, IrinotecanDrug
Paclitaxel, Docetaxel, Irinotecan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Until death, assessed up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.